ERBB2 and triple-negative breast carcinoma: Predominantly patients (73.8%) were hormone positive (either oestrogen receptor (ER) or progesterone receptor (PR) or both) and of luminal A or B subtype, followed by 70 (18.2%) and 31 (8.3%) patients each in triple-negative breast cancer (TNBC) and HER2 enriched subtypes.